Calvin Chan
Company: Bristol Myers Squibb
Job title: Associate Director, Allogeneic
Cell Therapy Process Platform
Email: Calvin.Chan@bms.com
Bio:
Calvin is currently serving as a CMC leader and the Allogeneic Drug Product Process Development lead at Bristol Myers Squibb in Seattle, WA. He joined BMS via the acquisition of Celgene and Juno Therapeutics. As an early member of Juno during its startup period, he was part of the PD team that developed the initial manufacturing process that later became the company’s expansion platform. He then served as a PD team leader on the company’s novel NEX-T process platform. Calvin has a strong interest in process technologies having developed and integrated numerous systems during his time at Juno, including cell separation, gene editing, and cell washing technologies. His broad understanding of early phase process integration led him to build the company’s first allogeneic platform, which he currently serves as its CMC leader.
Prior to joining Juno, he developed immunomagnetic cell separation products at STEMCELL Technologies and researched viral transduction enhancing molecules while studying Chemical and Biological Engineering at the University of British Columbia in Vancouver, Canada.
Location: Seattle, Washington, USA